(Reuters) -Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses. The drugmaker also forecast third-quarter adjusted earnings per share in the range of $1.74 to $1.78, according to the filing. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Berlin (dpa) - Many women, younger ones too, wonder when they'll enter the menopause, the…
There are many habits you can teach your children to help prevent the spread of…
नई दिल्ली,29 अगस्त: सतीश सनपाल, जो यूएई स्थित उद्यमी और व्यवसायिक नेता हैं, ऐसे नेतृत्व…
सूरत फ्यूचर फाउंडेशन और शक्ति ग्रुप कंपनीज की इंडिया पोस्ट (सूरत डिवीज़न) के सहयोगसे पहल;…
More and more people are trusting influencers over doctors on health advice, despite many posts…
Here’s everything you need to know about diminishing under-eye bags – without in-clinic treatments. London…